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Background: We have identified candidate protein and microRNA (miRNA) biomarkers for dyspnea by studying
serum, lavage fluid, and urine from military personnel who reported serious respiratory symptoms after they were
deployed to Iraq or Afghanistan.
Methods: Forty-seven soldiers with the complaint of dyspnea who enrolled in the STudy of Active Duty Military
Personnel for Environmental Dust Exposure (STAMPEDE) underwent comprehensive pulmonary evaluations at the
San Antonio Military Medical Center. The evaluation included fiber-optic bronchoscopy with bronchoalveolar lavage.
The clinical findings from the STAMPEDE subjects pointed to seven general underlying diagnoses or findings
including airway hyperreactivity, asthma, low diffusivity of carbon monoxide, and abnormal cell counts. The largest
category was undiagnosed. As an exploratory study, not a classification study, we profiled proteins or miRNAs in
lavage fluid, serum, or urine in this group to look for any underlying molecular patterns that might lead to
biomarkers. Proteins in lavage fluid and urine were identified by accurate mass tag (database-driven) proteomics
methods while miRNAs were profiled by a hybridization assay applied to serum, urine, and lavage fluid.
Results: Over seventy differentially expressed proteins were reliably identified both from lavage and from urine in
forty-eight dyspnea subjects compared to fifteen controls with no known lung disorder. Six of these proteins
were detected both in urine and lavage. One group of subjects was distinguished from controls by expressing a
characteristic group of proteins. A related group of dyspnea subjects expressed a unique group of miRNAs that
included one miRNA that was differentially overexpressed in all three fluids studied. The levels of several miRNAs
also showed modest but direct associations with several standard clinical measures of lung health such as forced
vital capacity or gas exchange efficiency.
Conclusions: Candidate proteins and miRNAs associated with the general diagnosis of dyspnea have been
identified in subjects with differing medical diagnoses. Since these markers can be measured in readily obtained
clinical samples, further studies are possible that test the value of these findings in more formal classification or
case–control studies in much larger cohorts of subjects with specific lung diseases such as asthma, emphysema, or
some other well-defined lung disease.
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Over 2.5 million military personnel have served in
Southwest Asia since 2002 to the present, as part of Op-
eration Iraqi Freedom, Operation Enduring Freedom, or
more recently Operation New Dawn. The majority of
these people were regularly exposed to geologic dust or
other airborne particulate matter or toxic substances.
After deployment overseas, some military personnel
have reported new respiratory symptoms generally de-
scribed as dyspnea that required further medical evalu-
ation. The ‘STudy of Active Duty Military Personnel for
Environmental Deployment Exposure’ (STAMPEDE)
was sanctioned by the U.S. Department of Defense expli-
citly to evaluate military personnel who have recurrent
or persistent dyspnea after deployment [1]. Our goal was
to work with the STAMPEDE project to discover mo-
lecular signatures or objective biomarkers of lung dis-
ease in these individuals.
Ours was an exploratory project, since no underlying
disease had been diagnosed in the STAMPEDE subjects.
Biomarkers have been reported for dyspnea, but only
when it is secondary to heart failure, myocardial infarc-
tion, or pulmonary infarction [2] all of which had been
excluded from the STAMPEDE subjects. Even though
biomarkers have been reported for different forms of
asthma [3-5] and specific patterns of miRNAs and pro-
teins have been reported for chronic obstructive pul-
monary disease [6,7] or idiopathic pulmonary fibrosis [8]
an assay based only on these markers might miss other
lung diseases. We also decided to test urine since it has
been studied as a source for protein markers of kidney
diseases [9,10] or prostate cancer [11,12]. Urine miRNAs
have been reported as biomarkers of polycystic kidney
disease [13]. Since the rationale for STAMPEDE was to
establish a diagnosis, the novelty of our approach was
to profile both proteins and miRNAs in samples of
BAL, urine, and serum from a group of soldiers whose
dyspnea was worsening, but where heart disease was
not suspected.
By comparing subjects who self-reported with dyspnea
to control individuals, we established protein profiles
from BAL fluid and urine. We also profiled miRNAs in
samples of BAL, urine, and serum. Both protein and
miRNA profiles from bronchoalveolar lavage BAL read-
ily classified most subjects with dyspnea from controls.
We also identified subsets of STAMPEDE subjects with
groupings of differentially expressed proteins or miR-
NAs, which would be consistent with a shared under-
lying pathology and a common diagnosis related to
asthma or possibly an obstructive lung disease. Some
differentially expressed miRNAs directly correlated with
abnormal measures of lung function, as recorded on
their medical charts. We also found that some differen-
tially expressed protein or miRNAs in subjects withdyspnea that were detected in BAL were also detected in
urine or serum or in all three fluids.
The molecular profiles we established from the BAL
samples from the fifteen control individuals begin to de-
fine the state of the normal lung. These protein and
miRNA biomarkers may be valuable as a general refer-
ence for a normal, healthy lung since the healthy lung
profiles represent lung ‘wellness’ at least for these indi-
viduals. Biomarkers for healthy lungs is of broader inter-
est in the context of personalized medicine and also for
judging progressive changes in the status of the lung
after surgery, recovery from a disease, or treatment with
a drug. This was an exploratory study. The ultimate goal,
after testing the candidate markers presented here in a
larger, rigorous case–control classification study in pa-
tients with a well-defined type of lung disease will be to
define valid markers that help with lung disease diagno-
sis, disease progression, or response to drug therapy.
Methods
Ethics statement
The project was conducted in compliance with U.S. 32
CFR 219 (“Common Rule”) as administered within the
United States Department of Defense (DoD). The Com-
mon Rule is derived from the basic ethical principles
espoused in the Belmont Report (http://ohsr.od.nih.gov/
guidelines/belmont.html). This project utilized de-
identified BAL fluid, urine, and serum samples acquired
by military researchers at San Antonio Military Medical
Center. Written informed consent was obtained in ad-
vance from all study participants. The use of these sam-
ples was approved at San Antonio Military Medical
Center under IRB protocol 363715. Participation in
this research by the Institute for Systems Biology under
protocol 2012.0007 which was also approved by the
Western Institutional Review Board (Registration #00000533).
The United States Army Medical Research and Materiel
Command Human Research Protection Office concurred
with the determination of the Western Institutional
Review Board.
Study participants
Soldiers with post-deployment respiratory symptoms were
referred to the STAMPEDE protocol at San Antonio
Military Medical Center from 2011 to 2013 [1]. Study
subjects had returned from deployment to Southwest
Asia within the past six months and complained of new
onset respiratory symptoms, primarily dyspnea. All par-
ticipants underwent a standard evaluation with full pul-
monary function studies, high resolution chest CT
scans, methacholine challenge testing and other testing
such as laryngoscopy or cardiopulmonary exercise test-
ing as clinically appropriate. The standard evaluation in-
cluded flexible bronchoscopy from which BAL fluid was
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180 cc normal saline instilled (60 cc × 3). The BAL fluid
was used to obtain cell counts, flow cytometry and cyto-
kine levels and a portion was sent to the Institute
for Systems Biology (ISB) for miRNA profiling and to
Pacific Northwest National Labs (PNNL) for proteomics
profiling. The morning urine was collected in a sterile
specimen collection container on the day of the bron-
choscopy. Samples were then placed on ice prior to cen-
trifugation at 1500 RCF for 10 minutes at 4°C. After
centrifugation, the sample was transferred to 3 cryovials
and then stored at −80°C before analysis. Two Greiner
Bio-One Vacuette red top with clot activator (RN 456089)
collection tubes are used to collect blood on the same day
as the bronchoscopy procedure. Once collected, the tubes
were inverted 5 to 6 times to mix the clot activator and
blood before a 30–45 minute incubation period at room
temperature with the tubes in an upright positon. After
clotting, the tubes were centrifuged for 10 minutes at
1200 RCF and 4°C. After centrifugation the supernatant
serum was transferred into 2 cryovials and then stored
at −80°C before analysis.
BAL and urine proteins were analyzed at PNNL.
Serum proteins were not profiled because the added cost
and complexity was beyond the scope of our effort. MiR-
NAs from BAL, urine, and serum were profiled at ISB.
Basic demographic information about the STAMPEDE
subjects was summarized [1] while information for
the control subjects is summarized in Additional file 1
and Table 1.
BAL sample preparation for proteome analysis
Samples (ranging from 0.46 to 1.90 mL) were thawed,
desalted, and concentrated with Amicon 3 K MWCO
spin filters (EMD Millipore, Billerica, MA). First, the fil-
ters were washed with 4 mL of 100 mM NH4HCO3
(buffer) and centrifuged at 4,000 × g for 40 minutes at
4°C. Next, the samples were applied to the filters and
buffer was added to adjust the volume to 4 mL, then
centrifuged at 4000 × g, 4°C for 45 minutes. Samples
were washed by filling the filter portion with 4 mL of
buffer (ensuring resuspension of the sample from the
bottom of the filter) and then centrifuged again for
75 minutes to ensure the dead volume was reached. The
samples were transferred from the filter portion of each
concentrator to a 2.0 mL microcentrifuge tube. The fil-
ters were rinsed by adding 100 μL of buffer, vortexing
briefly and then using a pipet tip to “wash” the two
membranes 3× each. Then the wash sample was com-
bined with the main sample. Next, the volume of each
sample was measured and normalized (adjusted) to
match the largest volume of the set of samples being
processed together. The protein concentration of each
sample was calculated by a Bicinchoninic (BCA) assay.Urea and dithiothreitol (DTT) were added from stock
solutions to final concentrations of ~8 M and 5 mM, re-
spectively and the samples were reduced and denatured
at 60°C for 30 minutes. Iodoacetamide was added to
40 mM and samples were incubated at 37°C for 1 hour
to alkylate. The samples were diluted eight-fold with
buffer, and CaCl2 was added to 1 mM. Samples were
digested with trypsin (Affymetrix/USB; Santa Clara,
CA) in a 1:50 (w:w) ratio of trypsin to protein at 37°C
for 3 hours. Samples were purified on C18 solid phase
extraction ‘Discovery’ columns (Supelco-Sigma-Aldrich,
Bellefonte, PA) followed by concentration, assaying pep-
tide concentration using the BCA protein assay (Thermo
Scientific Pierce; Rockford, IL), and diluted to 0.5 μg/μL
for mass spectrometry (MS) analysis.
Urine sample preparation for proteome analysis
The urine samples were processed using an epMotion
device (Eppendorf, Hauppauge, NY) which was used to
automatically pipette and process samples: 500 μl of
each urine sample was loaded into a 1.0 mL 96-well
plate and concentrated to dryness. Next, 107 μL of liquid
8 M urea was added to the dried urine, vortexed, and
then briefly centrifuged. After a 50-fold dilution the pro-
tein concentration was assayed by the BCA procedure,
followed by addition of DTT to 8.3 mM. The plate was
vortexed, centrifuged briefly, and incubated for 1 hour
with shaking. Iodoacetamide was added to 36 mM and
the plate was incubated at 37°C for 1 hour in the dark
with shaking. The samples were then diluted 8-fold with
100 mM NH4HCO3 (buffer), CaCl2 was added to 1 mM,
and trypsin was added in a 1:50 trypsin:protein (w:w) ra-
tio. The plate was incubated at 37°C for 3 hours with
shaking. Samples were purified as described above on
C18 columns (Agilent, Santa Clara, CA), concentrated,
re-assayed for protein concentration, and diluted to 0.3
ug/uL for MS analysis.
Reversed phase liquid chromatography (RPLC) separation
and MS(/MS) acquisition
The liquid chromatography (LC) system was custom built
at PNNL using two Agilent 1200 nanoflow pumps and one
Isco constant pressure capillary pump (Teledyne-Isco,
Lincoln, NE), various Valco valves (Valco Instruments Co.,
Houston, TX), and a PAL autosampler (Leap Technologies,
Carrboro, NC). Reversed-phase columns were prepared in-
house by slurry packing 3-μm Jupiter C18 (Phenomenex,
Torrence, CA) into 35-cm × 360 μm o.d. × 75 μm i.d fused
silica (Polymicro Technologies Inc., Phoenix, AZ) using a
1-cm sol–gel frit for media retention (unpublished PNNL
variation of the method of Maiolica et al. [14]. Trapping
columns were similar but used a 4 cm length of 100 μm
i.d. fused silica that was fritted on both ends. Mobile
phases consisted of 0.1% formic acid in water (A) and 0.1%
Table 1 Subject numbers and clinical diagnoses













13 Low DLCO 1
14 Air Trapping 1
15 constrictive bronchiolitis 1




20 Abnormal Cell Count
21 Airway Hyperreactivity 1
22 Asthma
23 COPD 1
24 Abnormal Cell Count





30 Abnormal Cell Count
31 Undiagnosed










42 Excessive dynamic airway collapse
43 GERD/AHR
Table 1 Subject numbers and clinical diagnoses
(Continued)
44 Abnormal Cell Count 2




Legend: DLCO – diffusing capacity for carbon monoxide; GERD/AHR –
gastroesophageal reflux with secondary airway hyperreactivity; VCD – vocal
cord dysfunction.
Brown et al. BMC Medical Genomics 2014, 7:58 Page 4 of 18
http://www.biomedcentral.com/1755-8794/7/58formic acid acetonitrile (B) operated at 300 nL/min with a
gradient profile as follows (min: %B); 0:5, 2:8, 20:12, 70:35,
97:60, 100: 95. Sample injection occurred 40 min prior to
beginning the gradient while data acquisition lagged the
gradient start and end times by 10 min to account for col-
umn dead volume that allowed for the tightest overlap pos-
sible in two-column operation. Two-column operation also
allowed for columns to be ‘washed’ (shortened gradients)
and re-generated off-line.
MS analysis was performed using a Velos Orbitrap
mass spectrometer (Thermo Scientific, San Jose, CA)
outfitted with a custom electrospray ionization interface.
Electrospray emitters were custom made by chemically
etching 150 um o.d. × 20 um i.d. fused silica [15]. The
heated capillary temperature and spray voltage were
350°C and 2.2 kV, respectively. Data was acquired for
100 min after a 10 min delay from when the gradient
started. Orbitrap spectra (AGC 1 × 106) were collected
from 400–2000 m/z at a resolution of 60 k followed by
data-dependent HCD MS/MS (collision energy 32%,
AGC 5 × 104) of the ten most abundant ions, excluding
single charge states. A dynamic exclusion time of 60 sec
was used to discriminate against previously analyzed
ions using a 0.55 to 1.55 Da mass window.
Mass spectrometry data analysis
Accurate mass and time (AMT) tag [16-19] results were
filtered for a mass error less than 3 ppm and by statis-
tical tools for AMT tag confidence [20] for a uniqueness
probability score greater than 0.5 and a false discovery
rate (FDR) threshold < 10%. The Accurate Mass and
Time (AMT) tag approach to proteomics we used is
a peak area-based form of quantification for high-
throughput proteomics. It has some advantages over la-
beling techniques for large samples sizes. But, compared
to labeling techniques it can have a higher peptide false
discovery rate. As such, the <10% peptide false discovery
rate refers only to the complexity of this specific AMT
Tag database which is simply based on mass and elution
times. But since we used multiple unique peptides for
protein identifications, the overall protein false discovery
rate is much lower than the peptide false discovery rate
[17,21]. The resulting datasets were log2 transformed.
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Mahalanobis distance squared values associated with the
peptide abundance vector (rMd-PAV) and a p-value
threshold less than 0.001 as recommended by the devel-
opers of the algorithm [22]. The optimal normalization
algorithm was determined by ‘Statistical procedure for
the analysis of peptide abundance normalization strat-
egies’ (SPANS: [20]) to be a mean center with the rank
invariant peptide (RIP) selection having a p-value thresh-
old of 0.1 for the BAL and a mean center with the top
L Order Statistics (LOS) peptide selection having a
p-value threshold of 0.05 for the urine datasets. The
correlation scores were summarized between datasets
derived from different individuals as shown (Additional
file 2). A probabilistic principal component analysis,
within the pcaMethods package version 1.50.0(4) in R
version (3.0.0; 64-bit), was performed on the datasets
containing missing values (Additional file 3). The enrich-
ment analysis of GO biological processes terms for key
groups of proteins was performed using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID, ver 6.7) software [23].
Statistical analysis
Hypothesis tests were performed with MSstats version
1.0.0 [24], with missing-action set to remove, to determine
statistical differences in protein abundance between con-
trol and disease samples. P-values were corrected for mul-
tiple comparisons using the Benjamini-Hochberg p-value
adjustment [25]. For heatmaps, protein abundance vectors
were arranged by ascending fold-difference. All statis-
tical tests were performed with R [26]. The net result of
the removal of outliers and the application of the filter-
ing steps described above was to identify 79 proteins de-
rived from BAL and 74 proteins from urine that were
differentially expressed in the dyspnea subjects and con-
trols as shown in the analysis figures, below. The overlap
rate for proteins between different subjects is given on the
heatmaps, below or in histograms (data not shown). The
BAL and urine protein abundances followed approxi-
mately normal distributions as shown by quantile plots
(Additional file 4).
MicroRNA analysis
RNA enriched for miRNA was isolated from 250 μL ali-
quots of bronchial alveolar lavage fluid, 150 μL aliquots
of serum, and 250 μL aliquots of urine from STAM-
PEDE subjects (n = 47) or control individuals (n = 15) by
using the miRNeasy mini kit (Qiagen, cat. 217 004). The
yields of total cell RNA from these samples were typic-
ally 30 nanograms or lower. The concentrations of about
800 human miRNAs were determined by using the
NanoString nCounter human miRNA expression assay
kit version 2.1 following the manufacturer’s instructions(NanoString Technologies, Seattle WA). This quantita-
tion method is based on hybridization of a miRNA to
complementary oligonucleotides that also carry func-
tional groups for purification and fluorescent tags for de-
tection [27]. Several samples from urine, serum, or
lavage were analyzed more than once which let us assess
the reproducibility of the RNA isolation and the Nano-
String profiles. After normalization against a global
mean and correction for background (greater than 50
counts), typical mean miRNA levels from two replicate
experiments (serum, BAL) or three replicates (urine)
were plotted (Additional file 5). Standard errors of the
mean were typically less than 10% of the mean. Selected
miRNA levels measured by NanoString profiling were
verified in a subset of STAMPEDE subjects and controls
by RT-PCR studies. RNA was isolated from lavage as de-
scribed above, and reverse transcribed (Qiagen miScript
II RT kit, cat. 218161). Primers specific for miRNAs
187-3p, 371a-5p, 212-3p, 1915-3p, 4516, 320e, and 630
were purchased from Qiagen and quantitative RT-PCR
was completed as described [28]. The RT-PCR results
substantially confirmed the NanoString levels for several
differentially expressed miRNAs that helped classify one
sub-set of dyspnea subjects (Additional file 6).
For identification of sub-groups by cluster analysis or
correlation analysis, the NanoString data for replicate
measurements (about 1/3 of all samples) were averaged.
The data was then normalized by a factor derived from
the geometric mean of the positive controls. Next, a
background correction was applied, which was based on
the mean plus two standard deviations of the negative
controls. Finally, the data was again normalized using a
factor calculated from the geometric mean of the highly
abundant probes. These steps were performed using the
R package NanoStringNorm [29]. Next, the normalized,
background corrected data was log2-transformed. Then,
using the Bioconductor package ‘LIMMA’ [30], differen-
tially expressed miRNAs between the STAMPEDE and
control groups we identified. P-values from the moder-
ated t-test and fold-changes between groups were ob-
tained and differentially expressed miRNAs were
identified by the criteria of p-values less than 0.01 and
fold-changes greater than ±2-fold. Pearson correlation
coefficients were calculated between several numerically
continuous medical chart parameters and selected
miRNA values.
Results
Proteomics analysis of lung fluid
Lung fluid was obtained by performing bronchoalveolar
lavage on 15 control and 47 STAMPEDE subjects with
dyspnea. Proteins were extracted and prepared for ana-
lysis by liquid chromatography coupled with online high
resolution mass spectrometry and low resolution tandem
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proach was used to analyze the datasets produced by the
mass spectrometer. An rMd-PAVS analysis [22] identi-
fied outliers with a p-value < 0.001, 2 controls and 7
disease samples, which were removed from the analysis.
Subsequent comparisons were between 40 dyspnea and
13 control profiles. The analysis identified 12,340 unique
peptides corresponding to 987 proteins. A SPANS analysis
[20] based on an in-house developed R application [26]
was used to determine the optimal normalization for
the peptide abundance values. The optimal normalization
was mean-centered, using rank invariant selected pep-
tides with a p-value > 0.10. An MSstats analysis [22] was
performed removing proteins with insufficient observa-
tions to perform the hypothesis test. The removal of
proteins with insufficient observations resulted in 652
proteins, of which 79 (~12%) showed a significant dif-
ference in abundance (p-value < 0.05) between control
and disease (66 proteins significantly greater and 13 sig-
nificantly lower in disease compared to control). The
effects of these filters on the data are illustrated by
the scatter plot presented in Figure 1. The 79 proteins
were further analyzed by one-dimensional cluster analysis
across all informative study subjects which were readily
distinguished from controls as shown in Additional file 7.
The 79 BAL proteins are listed by their UniProt identi-
fiers in Additional file 8. All were used to search for GO
terms. A sub-set of these proteins returned gene on-
togeny (GO) terms (p values <0.01) for digestion (ACE,
TRY6, TFF3, AMY2B), sterol or cholesterol or lipid
homeostasis (APOA1, APOA2, FABP4), and the pro-
teins APOA1 and APOA2 also returned terms for nega-
tive regulation of very-low-density lipoprotein particle
remodeling; regulation of cytokine secretion during im-
mune response; and negative regulation of cytokine se-
cretion during immune response as summarized in
Additional file 9. These GO terms are generally consist-
ent with tissue repair or remodeling or leakage of the
blood into the lung.
Proteomic analysis of urine samples
Proteins were extracted from urine obtained from 15
controls and 48 dyspnea individuals and analyzed by
LC-MS(/MS) as described above. An rMd-PAVS analysis
[22] identified outliers, 3 samples from the disease
group, which were removed from the analysis, leaving a
total of 45 samples in the dyspnea group. These dyspnea
profiles were compared to the 15 control urine profiles.
The analysis identified 9,330 unique peptides corre-
sponding to 846 proteins. Peptide abundances were nor-
malized and proteins with insufficient observations were
removed as described above. The optimal normalization
was median-centered, using the top L Order Statistics
peptide selection, with L being 614. The effects of thesefilters on the urine data are illustrated by the volcano
plot presented in Figure 1. The removal of proteins
with insufficient observations resulted in 695 proteins,
which 74 (~11%) showed a significant difference in
abundance (p-value < 0.05) between control and disease
(57 proteins significantly greater and 17 significantly lower
in the dyspnea group compared to control). Differentially
expressed proteins derived from urine readily distinguished
dyspnea subjects from controls (Additional file 10). The 74
proteins differentially expressed in urine are listed by their
UniProt identifiers in Additional file 8. A sub-set of these
proteins returned GO terms (p-values <0.06) for cell adhe-
sion (AMBP, PVR, WISP2, CADM4, CD44, CD99); regula-
tion of growth (WISP2, CD44, CSF1, VGF); regulation of
cell migration, locomotion, or cell motion (CSF1, ROBO4,
THY1); wound healing (HMCN1, CD44, CD59) all of
which are again generally consistent with tissue remodeling
(Additional file 9).
Protein found in BAL and urine samples
Six proteins TRY6, KV404, K2C1, HPT, FETUA, and
TFF3 were differentially expressed in STAMPEDE sub-
jects relative to controls and appeared in both in BAL
and urine. All six of these were generally higher in BAL
or urine from dyspnea subjects, except for K2C1 and
TRY6 which were higher in control urine rather than
urine from dyspnea subjects. That these proteins were
detected in both fluids, at least raises the possibility that
they could have originated in the lung, passed into the
blood stream, and were excreted in the urine (Additional
file 8). After unsupervised cluster analysis of the BAL
proteins shown in Figure 2, a sub-set of dyspnea subjects
that co-expressed a group of proteins was recognized.
This group, designated with the yellow oval in Figure 2
includes subjects 21, 13, 46, 15, 9, 25, 17, 19, 36, and 35.
The mean expression levels of these thirteen proteins in
the controls, the STAMPEDE subjects and the STAM-
PEDE sub-set mentioned above along with other statis-
tical parameters and their common names are listed
Tables 2 and 3. The proteins expressed in this STAM-
PEDE sub-group include many commonly found in
blood plasma (A2MG, APOA2, APOA1) or in red blood
cells (HBA and HBB) which would be consistent with
bleeding or tissue remodeling (or conceivably, the bron-
choscopy procedure itself ). Five of these ten subjects
(13, 15, 17, 19 and 21) also expressed a common set of
miRNAs (see below) as might be expected if there were
a common underlying pathology in the lung. Other sub-
ject groups may also be recognized, for example, by
close inspection of the dendrograms that group the sam-
ples (Figure 2). The six proteins that were detected in
both urine and lavage as well as the thirteen proteins de-
tected in BAL fluid represent the best candidates for fur-
ther validation studies.
Figure 1 Scatterplot of lung fluid (left) and urine (right) proteins. Significant proteins have an adjusted p-value less than 0.05. Proteins with
significantly greater and lower abundance in disease are shown in red and green, respectively, with the actual number displayed at top of plot.
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MiRNAs in BAL samples were profiled from 47 STAM-
PEDE subjects with dyspnea and 15 control individuals
with no known lung abnormalities. While the Nano-
String profiling system can quantitate over 800 different
miRNAs, only about 50 of these were routinely detected
in typical BAL samples. This is typical for some body
fluids, although hundreds of miRNAs are typically found
in serum and urine samples [28]. The top twenty-three
miRNAs that were most frequently observed in dyspnea
or control profiles are listed in Table 4, which simply
presents molecular counts, after normalization. MiRNAs
1246, 1283, and 630 were found in all 62 samples (dys-
pnea and control) in this study, while 23 miRNAs were
detected in at least 56 of 62 (90%) of the samples pro-
filed. MiRNAs 4516, 630 and 320 were expressed in
most samples at high levels, but they did not distinguish
dyspnea subjects from controls as shown in Additional
file 5. The levels of many miRNAs such as 4443, 143-3p,
574-5p, and 378e were unchanged between dyspnea
samples and controls. These may represent miRNAs that
are usually expressed in the upper airways and would be
sampled by a typical bronchial lavage.Differential MiRNA expression in BAL fluid
Differentially expressed miRNAs between dyspnea sub-
jects and controls were identified in BAL, serum , and
urine were defined as having a ± 2-fold expression
change, a mean count greater than the global mean, and
a p-value less than 0.01. This is represented graphically
in Figure 3. Differentially expressed miRNAs selected by
these criteria were displayed after one- and two-
dimensional cluster analysis in Figure 4.
Two groups of dyspnea subjects could be distinguished
from controls on the basis of having a shared pattern of
miRNA expression. Subjects 16, 18, 13, 17, 15, 21, 12,
23, 14, & 11 defined one group and showed elevated ex-
pression of miRNAs 371a-5p, 187-3p, 1915-3p, 4488,
and 421. This group is prominent in the upper left cor-
ner of Figure 4b and will be referred to hereafter as
Group 1. Box plots for the difference between group 1
and the controls are given in Additional file 11. Some
other subjects (19, 6, 30, 27, 7, and 5) expressed three of
these five miRNAs and may be related to group 1. Like-
wise miRNAs 212-3p, 4532, and 489 were elevated in
many group 1subjects, but these miRNAs were ultim-
ately removed by the statistical tests applied to Figure 4.
Figure 2 Unsupervised cluster analysis of BAL and urine proteins. BAL proteins from Additional file 7 and urine proteins from Additional file 10
were re-clustered for control and STAMPEDE subjects. Protein abundances were scaled by z-score, with green and red representing 1 standard deviation
below and above the mean, respectively. The bar above the heatmap indicates controls (green) and disease (purple) subjects. The oval identified a subset
of subjects who expressed a group of proteins in common, as discussed in the text. Gray indicates that a protein was not detected for that individual.
Some individuals have multiple columns (e.g. D14 in 3B) which resulted from technical replicate analyses. These technical replicates clustered together.
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cantly higher than expression in the controls (p < 0.003)
or in the 37 other patients in the study (p <0.07 or
lower) as shown in Table 5.
A second group of subjects (subjects 34, 45, 44, 28, 35,
and 36) was recognized who expressed three miRNAs
(191-5p, let-7i-5p, 125b) at levels higher than controls but
less robustly than the miRNA expression observed in
group 1. This group shows much lower expression of miR-
NAs 371a-5p, 187-3p, 1915-3p, 4488, 421, 663a relative to
other subjects with dyspnea and the controls. These two
miRNA classification patterns are distinct from one an-
other as well as from the controls which may suggest dis-
tinct lung pathologies or clinical diagnoses.
MiRNA expression in urine and serum
MiRNAs were profiled in urine and serum from STAM-
PEDE subjects and controls and cluster analysis of thedifferentially expressed miRNAs are given in Additional
files 12 and 13. Unlike the group 1 subjects that shared a
profile of miRNA expression from BAL, no such pattern
was obvious from the cluster analysis of urine or serum.
But some miRNAs were co-expressed in two of the fluids
studied and one miRNA (371a-3p) was reliably detected in
all three fluids studied (Figure 5). Twenty miRNAs were
reliably detected and differentially expressed in both urine
and serum, while four miRNAs were expressed in both
lavage and urine and two miRNAs were expressed in both
lavage and serum. The elevation of mMiRNA 371a-5p ex-
pression in all three fluids was easily recognized in x-y
plots of all of the expression data taken pair-wise as shown
in Additional file 14, or when the normalized expression
levels of this miRNA were plotted for the subjects and
controls (Figure 6). MiRNAs in dyspnea subjects that are
found in both urine and serum may arise in tissues or or-
gans outside the lung as a result of the body’s response to
Table 2 Proteins upregulated in BAL from controls, STAMPEDE subjects and a subset STAMPEDE subjects (21, 13, 46,
15, 9, 25, 17, 19, 36, 35), that were identified after cluster analysis (Figure 2)
Control subjects STAMPEDE subjects Subset of STAMPEDE
subjects
STAMPEDE vs CONTROLS STAMPEDE subset vs controls
Entrez ID Mean ST DEV CV, % Mean ST DEV CV, % Mean ST DEV CV, % p value p value
A1AG1 18.69 0.40 2.1 19.49 0.52 2.7 19.98 0.44 2.2 0.00055429 5.95509E-07
A1BG 18.95 0.32 1.7 19.20 0.33 1.7 19.52 0.13 0.6 0.0001927 4.63441E-05
AACT 17.34 0.50 2.9 17.99 0.35 2.0 18.37 0.13 0.7 0.0010359 6.39218E-06
ANT3 17.62 0.39 2.2 18.15 0.35 1.9 18.50 0.17 0.9 0.00037815 3.80627E-06
HEMO 18.74 0.29 1.5 19.07 0.31 1.6 19.37 0.27 1.4 2.7297E-05 0.000126029
APOA1 17.42 1.22 7.0 18.53 0.91 4.9 19.10 0.52 2.7 9.4027E-05 0.000842961
APOA2 15.72 1.26 8.0 16.65 1.18 7.1 17.09 1.08 6.3 0.00057807 0.018670507
PZP 17.01 0.99 5.8 17.86 0.71 4.0 18.27 0.57 3.1 3.3055E-05 0.003711976
A2MG 16.74 0.85 5.1 17.24 0.63 3.6 17.56 0.59 3.4 1.9526E-05 0.024453179
HBA 16.29 1.93 11.9 17.48 1.60 9.1 18.29 1.78 9.8 1.4869E-05 0.025085649
HBB 15.96 1.94 12.1 17.67 1.51 8.6 18.42 1.71 9.3 7.2466E-06 0.006838885
HBD 16.42 2.08 12.7 17.90 1.71 9.5 18.64 2.24 12.0 5.1691E-07 0.014381261
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that is found in all three body fluids could originate in a
lung tissue and pass into the blood stream (and eventually
the urine) if it was derived from a wide-spread pathologic
process such as tissue remodeling that included vascular
leakage, and if its concentration was high enough. The
miRNAs most appropriate for validation studies were
those that defined groups 1 and 2 (Figure 4; Table 5).
Specific miRNAs are associated with clinical measures of
pulmonary function
We calculated Pearson’s correlations between measured
parameters of lung function and the large number of dif-
ferentially expressed miRNAs that were detected inTable 3 Proteins upregulated in BAL from a subset
STAMPEDE subjects (21, 13, 46, 15, 9, 25, 17, 19, 36, 35),
after cluster analysis (Figure 2)
BAL proteins; uniprot ID Protein name
ANT3 ADP/ATP translocase 3
AACT Alpha-1-antichymotrypsin





PZP Pregnancy zone protein (a protease inhibitor)
A2MG Alpha-2-macroglobulin
HBD Human beta defensin
HBA Hemoglobin, alpha chain
HBB Hemoglobin, beta chainBAL, serum, or urine. To explore the relationship be-
tween them, a hierarchical clustering method was ap-
plied to the negative log10 of the Pearson’s correlation
values as shown in Figure 7. In Figure 7a, miRNA 187-
3p levels in STAMPEDE subjects shows possibly signifi-
cant associations with diffusing capacity for carbon
monoxide (DLCO) as well as forced expiratory volume
at one second, percent of predicted (FEV1 (% pred)).
This miRNA was also detected as differentially expressed
between controls and STAMPEDEs in Figure 4. Several
differentially expressed miRNAs that were identified in
Figure 4, also had interesting correlations with clinical
parameters: miRNAs 187-3p, 1915-3p, 4488, 421, and
371a-5p (data not shown). Associations between miRNA
significantly expressed in serum with 15 clinical chart
parameters are presented in Figure 7b and scatter plots
of miRNA-574 against the data for residual volume
(RV) and total lung capacity (TLC (% pred)) are given
in Additional file 15. For urine, miRNAs 548p and
3141 showed potentially interesting associations with
many related measures of lung function including TLC
(% pred), DLCO (% pred), ERS DLCO (% pred) and
DLCO ACT. Some of these are plotted in more detail in
Additional file 13.
Discussion
In this study we profiled proteins and miRNAs in clin-
ical fluids to identify potential molecular markers for
underlying lung disease in military personnel who de-
ployed to Iraq or Afghanistan and were enrolled in the
Army’s STAMPEDE study. The intent of this study was
to identify proteins or miRNAs in soldiers who sought
medical attention because of dyspnea within six months














1246 62 (100) 204.8 243.2 14.6 144.2
1283 62 (100) 738.0 809.8 14.1 311.3
630 62 (100) 2719.4 1026.8 625.6 590.4
4516 61 (98) 4537.7 8310.6 37.8 6731.2
21-5p 61 (98) 946.7 1130.3 111.7 340.2
222-3p 61 (98) 126.2 134.1 11.3 37.0
25-3p 61 (98) 223.7 202.1 13.2 92.6
601 61 (98) 172.6 92.6 190.3 30.8
378e 60 (97) 321.0 310.7 18.5 150.5
574-5p 60 (97) 103.2 99.4 20.9 36.5
320e 60 (97) 3942.6 3182.3 84.6 2620.1
1183 59 (95) 184.7 237.6 12.5 98.4
598 59 (95) 204.3 249.7 18.0 109.2
363 59 (95) 188.8 224.9 38.3 118.2
143-3p 59 (95) 184.2 179.6 11.9 75.4
302d 59 (95) 156.3 137.0 19.4 51.3
4443 59 (95) 322.9 324.4 9.5 196.4
200a-3p 58 (94) 134.5 157.9 16.3 57.7
4454 58 (94) 1130.4 882.0 26.1 651.6
495 57 (92) 135.0 144.4 10.2 72.6
141-3p 56 (90) 93.8 111.6 9.5 27.8
761 56 (90) 108.5 123.1 16.3 48.3
570 56 (90) 119.2 91.9 46.3 34.7
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http://www.biomedcentral.com/1755-8794/7/58of redeployment. A retrospective review of veterans de-
ployed to Southwest Asia suggested a higher rate of
“new onset asthma” [31]. King et al., [32] reported a case
series of 39 patients with constrictive bronchiolitis based
on surgical lung biopsy; many of these patients also had
an exposure to a sulfur mine fire. Overall the number of
soldiers who self-reported with dyspnea to military treat-
ment facilities remained low, given the large number of
people who served in Iraq and Afghanistan (approxi-
mately 2.5 million) over the past ten years and the inci-
dence of asthma in the adult US population of about 8%
(www.cdc.gov/nchs/fastats/asthma.htm). For those sol-
diers with dyspnea, it is unclear whether this can be as-
cribed to solely to military service or whether it would
have developed regardless. In part this was the rationale
for the creation of the STAMPEDE project: to evaluate
as many soldiers with dyspnea as possible at one loca-
tion, develop diagnoses with conventional clinical tests,
and use the patient registry for possible follow-up care.
Samples of urine, serum and BAL were collected from
a first cohort of STAMPEDE subjects. Since provisionaldiagnoses have been established for the STAMPEDE
subjects, these diagnoses can be compared to the
groups of differentially expressed proteins or the miR-
NAs that these subjects expressed. If one or more of
the molecular profiles matches study subjects with
the same conventional diagnoses, the molecular pro-
files become candidate biomarkers for that diagnosis.
This would make it possible to supplement conven-
tional lung disease diagnosis with a molecular profile.
Such molecular profiles could become clinically useful
biomarker profiles after additional validation studies.
Highly specific and sensitive assays for serum-based
protein biomarkers of lung cancer progression based
on selective reaction monitoring (SRM) mass spec-
trometry are entering the clinic [33] and chip-based
ELISA platforms have been described that can simul-
taneously measure multiple serum protein biomarkers
from tiny samples of peripheral blood [34]. MiRNAs
are potentially well-suited as disease biomarkers since
they are present in virtually all body fluids [28] and
have proven to be extremely stable in clinical samples
of plasma, serum, urine, or BAL.
One group of six proteins was differentially expressed
in the BAL and urine of STAMPEDE subjects compared
to controls (Additional file 8) raising the possibility that
these could have originated in the lung and passed into
the urine. Further validation studies that could test for
associations between these proteins and specific lung
disorders could shift from accurate mass-tag or discov-
ery proteomics methods to SRM mass spectrometry
assays on small samples of BAL or urine. A second
group of thirteen proteins that are typically found in
plasma (AACT, A1AG1, A2MG) and others that are
intracellular (HBA, HBB, CAH2: Table 1) were differen-
tially expressed by a group of 10 STAMPEDE subjects
(Figure 2). Five of these ten STAMPEDE subjects (21,
13, 15, 17, & 19) also showed the ‘group 1’ miRNA ex-
pression profile while three subjects (46, 36, 35) showed
the second miRNA expression profile. Because of the
overlap between these candidate marker profiles, these
proteins should also be considered for validation studies.
The finding of HBB and HBA which form adult
hemoglobin in this group could suggest that lysed red
blood cells were collected in the BAL. While localized
bleeding could result from the bronchoscopy, it could
also signal a disease process with some degree of tissue
remodeling such as emphysema [35-37]. Follow-up stud-
ies could help choose between these possibilities.
We explored whether the two groups of STAMPEDE
subjects that were defined by their miRNA profiles might
have similar disease processes by comparing their pre-
liminary diagnoses. The STAMPEDE subjects (11–18,
21, & 23) with the group 1 miRNA expression profile
(Figure 4B) have provisional diagnoses of chronic obstructive
Figure 3 Criteria for differentially expressed miRNAs. The scatter plot illustrates the p-values as a function of fold-change that defined
significantly differentially expressed miRNAs. Sixteen DEmiRs that met the criteria of more or less than 2-fold over- or under expressed relative to
controls (log2 expression less than −1 or greater than +1) with p-values lower than 0.01 (−log102) are shown. Similar criteria were applied for the
selection of DEmiRNA from urine or serum.
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http://www.biomedcentral.com/1755-8794/7/58pulmonary disease, fixed obstruction, airway hyperreac-
tivity, air trapping, asthma, low DLCO (2 subjects), and
constrictive bronchiolitis. We suggest that these diagno-
ses are consistent with a general finding of chronic
airway disorders. The STAMPEDE subjects with the
second miRNA expression profile (up-regulation of
miR-191-5p, 71-5p, 125b-5p) had diagnoses of asthma
(subjects 28 & 34), undiagnosed (subject 36), negative
(subject 35), airway hyperreactivity (subject 43), abnor-
mal cell count on BAL only (subject 44), or isolated low
DLCO (subject 45). MiRNA 125b has been linked to in-
flammation [38]. In both groups of subjects having can-
didate biomarker signatures that are pointing to
different stages of asthma-related lung disease, valid-
ation studies in which miRNA profiles are repeated and
correlated with focused clinical tests become vitally im-
portant. Asthma may change over time: resolving in
some individuals while progressing to more serious
chronic conditions in others [39-41]. Based on the diag-
noses for these subjects (Table 1) we speculate that it is
entirely possible that the miRNA signature for group 2
subjects indicates a typical or early stage of asthma with
active inflammation, while the signature for group 1 in-
dicates a transitional condition which may have pre-
sented as asthma, but has now progressed through a
phase of airway obstruction towards emphysema or
COPD. Case/control or other validation studies could
help clarify the value of the biomarkers we propose, by
relating them to definite diagnoses.Of the miRNAs that make up the group 1 profile,
miR-371a-5p was strongly overexpressed in BAL and it
was the only miRNA that was similarly differentially
expressed in urine and serum as well BAL (Figure 6;
Additional file 14). This miRNA is rare in blood [42]
and it has not yet been linked to lung disorders. Thus
identifying the cellular source(s) for this miRNA by in
situ hybridization is an important follow-up goal, as well
as correlating its expression with lung dysfunction.
Mechanistically, miRNAs from the 371–373 family have
been implicated as negative regulators of dickkopf 1
mRNA, which in turn permits activation of Wnt path-
way signaling, which could lead to reactivation of cell
growth or lung tissue remodeling [43]. MiRNA-421, also
part of the group 1 signature was detected in urine as
well as BAL. This miRNA has been proposed as a regu-
lator of the DNA damage response, since it can be regu-
lated by N-myc and it targets ATM, a key regulator of
genome integrity and the DNA damage response [44,45].
Mir-421 has also been proposed as a regulator of pan-
creatic cancer [46] and as a biomarker for gastric cancer
[47]. The other miRNAs that defined group 1 (1915-3p,
187-3p, 4488) have not been studied well and they have
not been associated with lung disease before now.
MiRNA 191, detected as part of the group 2 profile from
lavage was also detected in serum. This miRNA was over-
expressed in lung cancer [48] and it is rare in blood [42].
We also noticed that the levels of certain miRNAs cor-
related with clinical parameters of lung function. The
ab
Figure 4 Cluster analysis of differentially expressed miRNAs from BAL. a. MiRNAs were clustered by their expression levels (one way
clustering). b. Both miRNA expression and subject order were clustered to help recognize similar groupings (two-way clustering). No lavage
sample was available for profiling from subject 33.
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set of all differentially expressed miRNAs and most nu-
merically continuous lung clinic chart parameters [1].
Most of the miRNAs that constituted the signatures for
group 1 and group 2 STAMPEDE subjects (Figure 4b)
that were established by hierarchical cluster analysis
were also detected by their extremely low Pearson’s cor-
relation values with parameters such as DLCO or FEV(Figure 7). This increases our confidence that the associ-
ations of these miRNAs with pathologies that affect lung
function, especially as measured by forced expiratory
volume or gas exchange (DLCO) are meaningful. We
recommend this approach for discovering new potential
associations, particularly for generation of groups of
miRNA candidates for subsequent validation studies.
There is precedent for this approach since in another
Table 5 MiRNAs that define group 1 of dyspnea subjects
MiRNA Mean st dev p vs controls p vs other subjects
187-3p 899 567 0.0009 0.0011
1915-3p 442 250 0.00048 0.00055
4488* 256 113 0.00031 0.00036
371a-3p** 266 163 0.00098 0.079
421 110 63 0.0027 0.005
1915-3p 442 250 0.00048 0.00055
Legend: p values between the levels of the indicated miRNAs in the subjects of
group 1 were calculated with the levels in the 15 controls or the subjects not in
group 1 by a simple t-test. *, an outlier value from subject 16 was excluded from
the calculations; **, a few other subjects expressed this miRNA at or above the
mean, but did not otherwise fit the criteria for inclusion in group 1.
miR-191-5p
Figure 5 Venn diagram that shows differentially expressed miRNAs th
serum, or urine from STAMPEDE subjects. MiR-371a-5p and 191-5p wer
miR-421, 631, and 1231 were detected; and miRNAs 371a-5p and 23a-3p, 1
100-5p, 494, 922, 450b-5p, 1273d, 504, 542-3p, and 124-3p were detected i
Brown et al. BMC Medical Genomics 2014, 7:58 Page 13 of 18
http://www.biomedcentral.com/1755-8794/7/58study, the levels of six miRNAs that were measured in
induced sputum of smokers and patients with COPD
showed correlations with FEV1 post (% pred) with r2
values ranging from 0.4 – 0.5 [49].
Protein and miRNA profiles from the control sample
donors in this study is valuable because for the first time
it establishes ‘wellness’ for normal or typical individuals,
not known to have active lung disorders. Biomarkers of
wellness as well as of diseases could be valuable in the
future to judge lung health in routine physicals, return
to normalcy after a lung procedure or disease, or a re-
sponse to drug therapy for a lung condition such as
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Figure 6 The levels of miR-371a-5p in BAL, serum, and urine in STAMPEDE subjects and controls.
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diseases could be especially valuable as part of the phys-
ical examination given at the time of recruitment, to
identify problems or susceptibilities early, or before de-
ployment to hazardous areas.
Another unexpected result was the finding that several
miRNAs were expressed by most subjects with or with-
out dyspnea. While some were expressed at about the
same level in all subjects, the levels of others varied
widely. We speculate that these may be derived from a
fundamental lung cell or tissue such as bronchial
smooth muscle or alveolar epithelium or alternatively
from a cell that enters the lung from the circulation such
as a macrophage, lymphocyte, or eosinophil. Departures
from low- or baseline expression could be an indication
of a disease or some other pathologic process. We are
also investigating whether any of the differentially
expressed miRNAs could be targeting the mRNAs for
some of the differentially expressed proteins that were
observed in this study.
Limitations on this work could include the fact that
more than one underlying disease may be represented in
the STAMPEDE subjects, since ‘dyspnea’ is a general de-
scription. We also profiled body fluids, not lung tissue it-
self and these profiles probably differ. Nonetheless some
of the miRNAs that we detected have also been reported
in studies of asthma or COPD. Two miRNAs we de-
tected in serum (miR-223-3p and 15b-5p) we previously
reported as being up-regulated in lung tissue from pa-
tients with COPD, compared with smokers with no lung
obstruction [6]. We detected miR-449c-5p in both urine
and serum of STAMPEDE subjects as well as miRs-449a
and 34c-5p in urine. In two recent reports, the miRsfrom the miR-449/34 families were dysregulated in bron-
chial epithelial cells derived from patients with COPD
[50] or asthma [51]. The miRNA expression pattern ob-
served here from subjects with dyspnea, in particular the
miRNAs that defined the group 1 subjects (371a-5p,
187-3p, 1915-3p, 4488, and 421) has not been reported
yet for any lung disease. None of the miRNAs we de-
tected as differentially expressed in lavage overlapped
with a group of 17 miRNAs that has been proposed as a
serum signature for non-small cell lung carcinoma
[52,53]. We did detect one of these proposed markers
(miR-1) in urine and another (miR-141-3p) in serum but
there was no match to the complete signature for this
type of lung cancer. Likewise, none of the miRs we re-
ported overlapped with top-scoring pairs of miRNAs
that were proposed as markers for three different pul-
monary diseases (pneumonia, asthma, lung cancer) al-
though miR-146a-5p, which we detected in serum
differs by only 2 nucleotides from miR-146b-5p which
had some diagnostic value in combination with other
miRNAs [54]. Comparisons such as the above to previ-
ous work must be considered tentative because of the
poor reproducibility between measurement platforms
(see for example, [55]).
The STAMPEDE subjects, like most patients who ex-
perience breathing difficulty for the first time and come
to the lung clinic for medical care do not know their
diagnosis in advance. This was the motivation for the
STAMPEDE study. Since dyspnea can be associated with
diverse underlying conditions, it should be no surprise
that the candidate markers we found were not clearly
linked to one or two discrete clinical endpoints. But the
patterns of markers we found were clearly separated
ab
c
Figure 7 Association of miRNA levels with clinical chart
parameters. Pearson correlations between different numerically
continuous measurements of lung function or physiology and
differentially expressed miRNAs were calculated for all STAMPEDE
subjects. For simplicity, the negative log10 of calculated Pearson
correlation values are displayed. Only relationships deemed to
be potentially significant with p-value < 0.03 were depicted.
a, BAL; b, Serum; c, Urine. DLCO, diffusing capacity for carbon
monoxide; DLCO/VA, diffusing capacity for carbon monoxide
adjusted for volume; ERS, European Respiratory Society; FEF25-75,
mid-expiratory flow; FEV1, forced expiratory volume at one second;
FVC, forced vital capacity; BD, bronchodilator; TLC, total lung
capacity; RV, residual volume; IOS, impulse oscillometry; R5, total
respiratory resistance; R20, proximal resistance; X5, distal capacitive
reactance; Fres, resonant frequency; AX, reactance area; MCT,
methacholine challenge testing; PFT, pulmonary function testing;
HGB, hemoglobin; HCT, hematocrit; CD4/CD8, CD4 to CD8 lymphocyte
ratio; WBC, white blood cell.
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sociated with more or less advanced forms of asthma,
based on our review of the available clinical findings.
This work reveals that accurate lung disease diagnosis,
even with excellent clinical support remains difficult,
which underscores the potential value of objective mo-
lecular markers. The diagnostic value of the candidate
markers we described can be judged in any future study
where subjects have a well-defined lung disease.
Conclusions
Profiling of proteins and miRNAs using advanced
methods can give insights into the most detailed patho-
logical as well as normal physiologic processes. The
marker groups we have identified in soldiers with dys-
pnea may be closely related to lung disorders such as
asthma, bronchiolitis, or COPD. As these correlations
are made the candidate markers we described would be
ready for validation studies and eventually, translation
into clinical trials. The ultimate outcome would be novel
platforms for new objective information to speed the re-
liable diagnosis of lung disorders.
Additional files
Additional file 1: Diagnoses and demographic data on STAMPEDE
and control subjects. See [1] for more details.
Additional file 2: Summary of correlation scores between datasets
representing individuals. Panels A, C, and E are of lung fluid proteomes
and panels B, D, and F are urine proteomes. The 56 bars in panel A and
the 60 bars in panel B represent the mean correlation (Pearson’s
correlation coefficient, r) for a dataset compared to its biological
replicates. The red horizontal line in panels A and B indicates the mean
correlation threshold used to distinguish outliers, for lung fluid and urine,
respectively. Outlier datasets are indicated by a red bar within the plots,
while controls are green and disease are purple. Panels C and D are
correlation heatmaps prior to outlier removal. The color of the cells in the
heatmap correspond to the pairwise correlation coefficients between the
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http://www.biomedcentral.com/1755-8794/7/58row/column datasets, with red representing a perfect correlation (+1)
and blue the minimal correlation value in the matrix. Panels E and F are
the correlation heatmaps after outliers have been removed. The green
and purple bars above and to the left of the correlation heatmaps
designate control and disease, respectively.
Additional file 3: PCA plot of BAL and urine datasets on left and
right, respectively. Each dot represents an individual with green
indicating control and purple designating disease individuals. Green and
purple ellipses indicate the distribution of each group within the
dimensions of the first and second principal components.
Additional file 4: Abundance and variance distributions for BAL
and urine proteins. (Upper left): normal quantile (Q-Q) plot of proteins
identified from BAL fluid; (Upper right): variance distributions for BAL
proteins from control subjects (green) or STAMPEDE subjects (violet);
(Lower left): normal Q-Q plot of proteins identified from urine; (lower
right): variance distributions for urine proteins from control subjects
(green) or STAMPEDE subjects (violet).
Additional file 5: Analysis of technical replicates of miRNA levels.
The mean normalized counts are displayed along with the standard error
of the mean. A: miRNA levels from two separate isolations from serum
from subject 1 were profiled; B: miRNA from three separate isolations
from urine from subject 1 were profiled; C: miRNA from two separate
isolations from BAL from subject 2 were profiled.
Additional file 6: RT-PCR analysis of selected miRNA levels and
comparison with NanoString levels. MiRNAs that classified STAMPEDE
subjects from controls (187-3p, 371a-5p, 212-3p, 1915-3p) and miRNAs
that were strongly expressed in BAL but did not discriminate STAMPEDE
subjects from controls (4516, 320e, and 630) were measured by quantitative
RT-PCR as described in Methods. RT-PCR amplifications were run in
quadruplicate for all samples and the results were averaged. The
average expression of these miRNAs as observed in STAMPEDE subjects
12–14 & 16–18 and in control subjects 1, 4–7, & 12 are compared.
STAMPEDE subjects 12–14 and 16–18 were classified together as
belonging to a sub-group that shared a similar profile of miRNA
expression which was quite distinct from the controls. A: Normalized
levels of the indicated miRNAs in STAMPEDE subjects (S-187, S-371, etc.)
or controls (C-187, C-371, etc.) by NanoString profiling. The standard
error of the mean is shown. B: Levels of the indicated miRNAs in
subjects or controls by RT-PCR. The standard error of the mean is shown.
Additional file 7: Heatmap of the 79 significantly different proteins
in lung fluid between control and disease individuals, designated
by the light and dark blue bars above the heatmap, respectively.
Protein abundance values were clustered by unsupervised hierarchical
clustering using Pearson’s correlation as a measure of distance and
complete agglomeration, which is default for the R ‘hclust’ method.
The protein abundance values were scaled using z-scores, with red
representing 1 standard deviation above the mean and green being 1
standard deviation below the mean. Uniprot accession identifiers for the
proteins are shown on the right side of the heatmap.
Additional file 8: Proteins reliably identified in common from BAL
(n = 79) and urine (n = 74) from Additional files 3 & 4 are listed by
their UniProt accession identifiers. The proteins in common from BAL
and urine are listed as well.
Additional file 9: A, Gene ontogeny terms (GO) for BAL or urine
proteins. Twenty-eight of seventy-nine proteins were used for this
search. B: Gene ontogeny terms (GO) for urine proteins. Thirty-seven of
seventy-four proteins were used for this analysis.
Additional file 10: Heatmap of the 74 significantly different
proteins in urine between control and disease individuals,
designated by the light and dark blue bars above the heatmap,
respectively. The protein abundance values were scaled using z-score,
with red representing 1 standard deviation above the mean and green
being 1 standard deviation below the mean. Uniprot accession identifiers
for the proteins are shown on the right side of the heatmap.
Additional file 11: Box plots for the levels of miR-187-3p, 371a-5p,
421, 1915-3p, and 4488 define STAMPEDE subjects in group 1
compared with controls. Group 1: STAMPEDE subjects 16, 18, 13, 17, 15,21, 12, 23, 14, & 11; Control: all 15 control subjects; Control + others:
controls plus STAMPEDE subjects exclusive of group 1.
Additional file 12: One way cluster analysis of 76 differentially
expressed miRNAs in urine.
Additional file 13: One way cluster analysis of 96 differentially
expressed miRNAs in serum.
Additional file 14: Pair-wise expression of miRNA in BAL, urine, or
serum. Upper left, the average expression of a specific miRNA (as the
log2 level) in urine plotted as a function of its average levels in BAL;
Upper right, miRNA expression in serum as a function of the levels in
BAL; Lower left, miRNA expression in urine as a function of the levels in
serum. The blue arrow identifies the expression of miRNA 371a-5p which
was elevated in all three samples from STAMPEDE subjects. While the
majority of the miRNA epression changes in BAL, urine, and serum
were independent of one another, miRNA 371a-5p was consistently
overexpressed in BAL, urine, and serum from STAMPEDE subjects.
Additional file 15: Plots of selected miRNAs that showed
associations with medical chart parameters by calculation of
Pearson correlations.
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